Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Decision Resources
Promise of Higher Prices is Naturally Attractive to Drug Makers, But Pharma May Find it Difficult to Convince Payers of the Value of Innovative Medicines, According to a New Report from Decision Resources
BURLINGTON, Mass., Dec. 9, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that payers are increasingly adopting value-based pricing as a way to focus their limited pharmaceutical budgets on drugs that meet genuine clinical needs and better reward manufacturers for developing such medicines. Value-based pricing is a method of pricing medicines based on willingness to pay or the perceived additional benefit of new drugs relative to established comparator therapies.
The Strategic Insights report entitled, Key Trends in Market Access: Implications for the Pharmaceutical Industry, notes that while the promise of higher prices is attractive to drug manufacturers, it may prove difficult for drug makers to convince some payers of the value of an innovative medication. Moreover, drugs that are not deemed to offer any advantages over established therapies will face a challenging pricing and reimbursement environment.
Major markets that use elements of value-based pricing include Australia, Belgium, Canada, Denmark, France, Germany, Italy, Japan, the Netherlands, Norway, South Korea, Spain, Sweden and the United Kingdom (beginning autumn 2014).
"Value-based pricing is increasingly common in mature pharmaceutical markets. European countries, in particular, are embracing this approach to pricing," said Decision Resources Group Vice President of Global Market Access Insights Neil Grubert, M.A. "Because there is such a wide range in the approaches to value-based pricing, it is important for pharmaceutical manufacturers to understand the exact requirements of each system at a very early stage in the drug development process. Errors in clinical trial design and endpoints could lead to market access delays and less advantageous pricing and reimbursement terms. Or, drugs could be excluded from reimbursement altogether."
About Strategic Insights
Strategic Insights is a new series of high-level, strategic reports from Decision Resources Group thought leaders, designed for corporate executives in the biopharma industry. The Strategic Insights series evaluates global industry trends that are shaping the healthcare market, and delivers targeted, actionable insight in an easy-to-read PowerPoint format.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks of their respective holders.
For more information, contact:
Decision Resources Group
©2012 PR Newswire. All Rights Reserved.